Thermo Fisher agreed to pay pay $26 per common share in cash for the company, totaling a sale of $3.1 billion. Credit: Shutterstock / SmartPhotoLab

Thermo Fisher Scientific, has struck a deal to buy Swedish proteomics firm Olink at a price of $3.1 billion.

Thermo Fisher agreed to pay $26 per common share in cash for the company, 74% of the closing price of Olink’s American Depositary Shares that trade on Nasdaq, before the announcement.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The transaction is set to be completed by 2024, subject to regional customary conditions, and will see Olink integrated into Thermo Fisher’s Life Sciences Solutions segment.

Jon Heimer, CEO of Olink said: “Olink is dedicated to improving the understanding of human biology by accelerating the use of next-generation proteomics and providing industry-leading data quality at unprecedented scale.

“Thermo Fisher’s deep life sciences expertise, global reach and proven operational excellence will enable significant opportunities for both customers and colleagues, while also providing immediate value to our shareholders.”

Thermo Fisher has said that Olink’s portfolio is home to 5,300 validated protein biomarker targets and has seen its work published in 1,400 scientific publications. As part of the deal, Thermo Fisher is also set to acquire the Swedish firm’s facilities in the Americas, Europe and Asia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Marc Casper, chairman of Thermo Fisher, added: “The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine.

“Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms. Our company is uniquely positioned to bring this technology to customers enabling them to meaningfully accelerate discovery and scientific breakthroughs. We look forward to welcoming Olink’s colleagues to Thermo Fisher.”

Additionally, Thermo Fisher has said that  Olink is on track to deliver over $200 million of revenue in 2024, and will increase the American company’s operating income by $125 million five years following the deal closing.